5 Key Takeaways

• 1

  The EU has approved the first pertuzumab biosimilar, POHERDY, for HER2-positive breast cancer, expanding treatment options in Europe.

• 2

  POHERDY's approval is based on comprehensive data demonstrating high similarity to Roche's PERJETA, including efficacy and safety.

• 3

  Genexine's GX-BP1 shows strong preclinical activity in resistant cancer models, achieving up to 96% tumor growth inhibition in combination therapies.

• 4

  NICE has recommended rozanolixizumab as the first treatment for uncontrolled generalized myasthenia gravis in adults, available through interim funding.

• 5

  Ecolab has opened a Bioprocessing Applications Lab in Korea to support biopharmaceutical manufacturers in optimizing purification workflows.